Rilapine

This classification denotes an antipsychotic agent with the molecular formula C22H20ClN3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7QCG0RP106, chemically known as (z)-2-chloro-10-(4-methyl-1-piperazinyl)-5h-dibenzo(a,d)cycloheptene-(delta(sup 5,alpha))-acetonitrile but generally known as rilapine, which bears US NIH Compound Identifier 6446980. European Medicines Agency schedules Rilapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10313MIG. The term RILAPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). RILAPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rilapine under HS 29335995 and SITC 51576. As of Q4 2014, RILAPINE remains the US FDA Preferred Term for this commodity. Rilapine bears US NLM identifiers UMLS ID C2699086 and NCI Concept Code C76445. SMILES: CLC1CC2C=C(N3CCN(CC3)C)C3C(/C(=C/C#N)C2CC1)CCCC3.